Results 11 to 20 of about 152 (81)

Moxifloxacin-Induced Bullous Acute Generalized Exanthematous Pustulosis (AGEP): A Case Report of a Rare Clinical Presentation. [PDF]

Case Rep Dermatol Med
Acute generalized exanthematous pustulosis (AGEP) is a severe cutaneous adverse reaction (SCAR) typically characterized by sterile pustules. The bullous variant of AGEP is exceptionally rare and represents a significant diagnostic challenge as it clinically mimics toxic epidermal necrolysis (TEN). We report the case of a 91‐year‐old woman who developed
Yeral M, Dasgin D, Aydogdu CT, Altinbas E, Celik SY, Bat B.   +5 more
europepmc   +2 more sources

A review on toxic epidermal necrolysis-like superficial wound lesions: Issue and challenge on 10 clinical entities. [PDF]

Int Wound J
Abstract Toxic epidermal necrolysis (TEN) is a severe skin reaction caused by extensive epidermal and mucosal necrosis. This clinical phenomenon is known as an acute syndrome of apoptotic pan‐epidermolysis (ASAP). The ASAP phenomenon is observed in conditions that mimic TEN, highlighting the challenge in distinguishing these conditions.
Abtahi-Naeini B, Pourmahdi-Boroujeni M, Rastegarnasab F, Emamjomeh A.   +3 more
europepmc   +2 more sources

Prospective longitudinal study of psychological sequelae, self-perception of body image, and quality of life in severe cutaneous adverse drug reactions: a case-control study [PDF]

Frontiers in Medicine
BackgroundSevere cutaneous adverse drug reactions (SCARs) are associated with mental health sequelae and reduced quality of life. However, existing research is limited by small retrospective cohorts, overrepresentation of high-income countries, lighter ...
Eddy M. Zitha, Aneliswa Mpungose, Lovemore Mapahla, Lovemore Mapahla, Lovemore Mapahla, Avumile Mankahla, Bukiwe Thwala, Mireille Porter, Nadine Teixeira, Jean M. Abrahams, Phuti Choshi, Helen Hoenck, Rhodine Smith, Laura Pirjol, Sipho Dlamini, Elizabeth Phillips, Jonny Peter, Rannakoe J. Lehloenya   +17 more
doaj   +2 more sources

Fixed drug eruption induced by Etoricoxib in Thailand: A case report [PDF]

Toxicology Reports
Etoricoxib, a commonly prescribed non-steroidal anti-inflammatory drug (NSAID), has been associated with adverse cutaneous reactions, including fixed drug eruption (FDE).
Metar Siriwattanasatorn, Atiwut Kamudhamas, Nakarin Sivapornpan, Mathavadee Noonpugdee, Chuntida Kamalashiran, Pratya Phetkate   +5 more
doaj   +2 more sources

Hypersensitivity Reactions to Gadolinium-Based Contrast Agents: Update From an Allergist's Point of View. [PDF]

Clin Transl Allergy
ABSTRACT Background The increasing use of Magnetic Resonance Imaging (MRI) has led to a rise in the administration of gadolinium‐based contrast agents (GBCAs), accompanied by a growing number of reported adverse events (AEs). Objective This review aims to provide an updated overview of hypersensitivity reactions (HSRs) to GBCAs, focusing on diagnostic ...
Losa F, Paoletti G, Costanzo G, Rizzini FL, Mauro M, Preziosi D, Rivolta F, Sangalli A, Toniato A, Traversi S, Vrenna A, Di Gioacchino M, Canonica GW, Heffler E, Costantino MT.   +14 more
europepmc   +2 more sources

A Saudi Woman with Ceftriaxone Induced Fixed Drug Eruption. [PDF]

Case Rep Dermatol Med
Background. A fixed drug eruption (FDE) is an immunological cutaneous adverse reaction, classified as a cutaneous adverse drug reaction (CADR) and characterized by well‐defined lichenoid lesions that occur at the same site each time. Ceftriaxone is a third‐generation antibiotic of cephalosporin antibiotics of the beta‐lactam antibiotic family, which ...
Al-Ansari RY, Almuhaish LA, Hassan KA, Fadoul T, Woodman A.   +4 more
europepmc   +2 more sources

Spectrum of offending drugs and cutaneous adverse drug reactions requiring hospitalisation in a tertiary South African hospital in TB/HIV endemic setting [PDF]

Frontiers in Allergy
IntroductionCutaneous immune-mediated adverse drug reactions are more prevalent in people with human immunodeficiency virus (PWH). Severe cutaneous adverse drug reactions (SCAR) are a life-threatening subset of cutaneous adverse drug reactions (CADRs ...
S. P. P. Konyana, N. F. Teixeira, L. Pirjol, B. Thwala, W. Nkoyane, M. Porter, F. Gxolo, E. Phillips, E. Phillips, R. Lehloenya, A. Mankahla, J. Peter   +11 more
doaj   +2 more sources

Severe bullous drug reaction after COVID‐19 mRNA vaccination

, 2022
JDDG: Journal der Deutschen Dermatologischen Gesellschaft, Volume 20, Issue 11, Page 1509-1511, November 2022.
Marie Luise Irmer, Alexander Nast, Franziska Ghoreschi, Annika Vogt, Kamran Ghoreschi   +4 more
wiley   +1 more source

Treatments for Severe Cutaneous Adverse Reactions

Journal of Immunology Research, Volume 2017, Issue 1, 2017., 2017
Severe cutaneous adverse reaction (SCAR) is life‐threatening. It consists of Stevens‐Johnson syndrome/toxic epidermal necrolysis (SJS/TEN), drug reaction with eosinophilia and systemic symptoms (DRESS), acute generalized exanthematous pustulosis (AGEP), and generalized bullous fixed drug eruptions (GBFDE).
Yung-Tsu Cho, Chia-Yu Chu, Riichiro Abe
wiley   +1 more source

Immunohistopathological Findings of Severe Cutaneous Adverse Drug Reactions

Journal of Immunology Research, Volume 2017, Issue 1, 2017., 2017
Diagnosis of severe cutaneous adverse drug reactions should involve immunohistopathological examination, which gives insight into the pathomechanisms of these disorders. The characteristic histological findings of erythema multiforme (EM), Stevens–Johnson syndrome (SJS), and toxic epidermal necrolysis (TEN) provide conclusive evidence demonstrating ...
Mari Orime, Wen-Hung Chung
wiley   +1 more source